WO2025215591 - MODIFIED VECTORS FOR XLA GENE THERAPY
National phase entry is expected:
Publication Number
WO/2025/215591
Publication Date
16.10.2025
International Application No.
PCT/IB2025/053804
International Filing Date
11.04.2025
Title **
[English]
MODIFIED VECTORS FOR XLA GENE THERAPY
[French]
VECTEURS MODIFIÉS POUR THÉRAPIE GÉNIQUE DE LA XLA
Applicants **
CSL BEHRING L.L.C.
SEATTLE CHILDREN’S HOSPITAL D/B/A SEATTLE CHILDREN’S RESEARCH INSTITUTE
Inventors
RAWLINGS, David J
KHAN, Iram F
CHEN, Chao-Guang
AESCHIMANN, Florian
Priority Data
63/633,225
12.04.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3026 | |
| EPO | Filing, Examination, Granting | 16509 | |
| Japan | Filing, Examination, Granting | 2513 | |
| South Korea | Filing, Examination, Granting | 2729 | |
| USA | Filing, Examination, Granting | 7590 |
Total:
32,367
Contact Us
Abstract[English]
This disclosure relates generally to vectors, typically viral vectors, useful for the treatment of X-linked agammaglobulinemia (XLA).[French]
La présente divulgation concerne de manière générale des vecteurs, typiquement des vecteurs viraux, utiles pour le traitement de l'agammaglobulinémie liée à X (XLA).